WO2005105022A1 - 育毛剤 - Google Patents
育毛剤 Download PDFInfo
- Publication number
- WO2005105022A1 WO2005105022A1 PCT/JP2004/009894 JP2004009894W WO2005105022A1 WO 2005105022 A1 WO2005105022 A1 WO 2005105022A1 JP 2004009894 W JP2004009894 W JP 2004009894W WO 2005105022 A1 WO2005105022 A1 WO 2005105022A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- iron
- hair
- ammonium
- acid
- sodium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Definitions
- the present invention relates to a hair growth agent having a hair growth action such as excellent hair loss prevention and hair growth effect used in the field of pharmaceuticals, quasi drugs or cosmetics, and more specifically, a hair growth agent containing 5-aminolevulinic acid as an active ingredient.
- the present invention relates to a hair restorer that uses a combination of monoaminorepric acids and iron compounds. Background art
- hair cosmetics have been developed for the purpose of preventing and improving alopecia. Due to the high proportion of alopecia in male alopecia, the application of a component with an anti-androgenic effect was examined, and the binding of dihydrotestosterone, an active testosterone, to the receptor was competitively inhibited. And those that inhibit testosterone 5-reductase, an enzyme that catalyzes the conversion of testosterone to dihydrotestosterone.
- the former is cyproterone acetate, and the latter is an and Ci stanone derivative, bicycloheptenone derivative, phenoxybutane derivative, tocopheryl quinone, trobolone derivative, ubiquinone, etc.
- 6- (1-piberidinyl) 1 2,4-pyrimidinediamin 1 3 Oxide (Minoxidil) (see, for example, US Pat. No. 4, 1 39, 6 19), cephalanthin, vitamin E derivative, carpronium chloride, urea (for example, Japanese Patent Laid-Open No. 7-2 6 7 8 30)
- Activating hair follicles including hair matrix cells such as those that have a blood circulation promoting effect on the scalp, adenosine, phosphoric acid, urogastron, baicalein, pantethine-S-sulfonic acid, and odd-chain fatty acid derivatives
- hair matrix cells such as those that have a blood circulation promoting effect on the scalp, adenosine, phosphoric acid, urogastron, baicalein, pantethine-S-sulfonic acid, and odd-chain fatty acid derivatives
- the application of those having the function to act is also being studied.
- An object of the present invention is to solve the problems in the use of external preparations for the head containing 5 monoaminorepric acids as active ingredients. To solve this problem, and to provide a hair restoration agent that has higher stability and safety, is simple to use, and has an excellent hair growth promoting action against hair loss, eyelashes, split hairs, whitening, etc. .
- the present inventors can use the various compounds in combination with 5-aminolevulinic acid so that the usage is simple and safe. Based on the assumption that a stable hair-growth effect may be achieved, a number of compounds were tested and earnestly studied, and as a result, hair removal and shading conditions when using 5-aminolevulinic acid alone became a problem. The present inventors have found that the problem can be avoided by using 5-aminorepric acid in combination with an iron compound, and have completed the present invention. Disclosure of the invention
- the present invention comprises a hair-restoring agent characterized by containing, as active ingredients, one or more compounds selected from 5-aminolevulinic acid or a salt thereof, or a derivative thereof, and an iron compound (claims). 1), the hair-restoring agent according to claim 1 (claim 2) further containing urea as an active ingredient, and the iron compound comprising ferrous citrate, sodium iron citrate, Ammonium iron phenate, iron acetate, iron oxalate, ferrous succinate, sodium iron succinate, ferrous pyrophosphate, ferric pyrophosphate, heme iron, dextran iron, iron lactate, darconic acid Ferrous iron, sodium diethylenetriaminepentaacetate, ammonium diethylenetriaminepentaacetate, sodium irondiaminediaminetetraacetate, ammonium irondiaminediamineacetate, The hair-restoring agent according to claim 1 or 2, which is one or more compounds selected from iron triethylenetetraamine, sodium iron dicarboxymethyldalta
- Claim 3 or 5-aminolevulinic acid or its A hair-growth method characterized by transdermally administering to the head a hair-growth agent comprising one or more compounds selected from salts or derivatives thereof and an iron compound as active ingredients (claims) 4) and a hair-growth method according to claim 4 (claim 5), wherein a hair-growth agent further containing urea as an active ingredient is transdermally administered to the head.
- FIG. 1 is a photograph showing a clinical experiment example of the hair restorer of the present invention.
- the upper left is taken at the start of application, the lower left is taken 4 weeks later, the upper right is taken 5 weeks later, and the lower right is taken 7 weeks later (July 12th).
- FIG. 2 is a photograph showing a clinical experiment example of the hair restorer of the present invention. The left image was taken at the start of application, and the right image was taken 4 weeks later.
- FIG. 3 is a photograph showing a clinical experiment example of the hair restorer of the present invention. The left image was taken at the start of application, and the right image was taken 4 weeks later.
- FIG. 4 is a photograph showing hair growth 20 days after application of the hair-restoring composition of the present invention to mice.
- the upper left shows an untreated mouse
- the upper right shows a mouse coated with 5% minoxidil
- the lower left shows a mouse coated with the No. 14 composition of the present invention.
- the hair restorer of the present invention is not particularly limited as long as it contains one or two or more compounds selected from 5-aminolevulinic acid or a salt thereof or a derivative thereof and an iron compound as active ingredients.
- the hair growth method of the present invention includes a hair growth agent containing, as active ingredients, one or more compounds selected from 5-aminolevulinic acid or a salt thereof, or a derivative thereof, and an iron compound.
- the 5-aminolevulinic acid is also referred to as ⁇ —aminolevulinic acid and is represented by the formula HO ⁇ C— (CH 2 ) 2 — (CO) — CH 2 — NH 2 It is a kind of amino acid (hereinafter referred to as 5-ALA).
- This 5-aminolevulinic acid is widely distributed in various organisms and is usually biosynthesized from succinyl Co A and glycine by 5-aminolevulinic acid synthase.
- This 5 monoaminorepric acid is also known as an intermediate of porphyrin biosynthesis.
- Examples of the salt of 5-aminolevulinic acid according to the present invention include hydrochloride, phosphate, nitrate, sulfate, acetate, propionate, butyrate, valerate, kenate, fumarate, and maleic acid.
- Examples include acid addition salts such as salts and malates, and metal salts such as sodium salts, potassium salts, and calcium salts. These salts are used as an aqueous solution, suspension or powder at the time of use, and the action is preferably the same as that of 5-aminorepric acid.
- Typical examples of the 5-aminorepric acid derivative used as an active ingredient of the hair restorer of the present invention include esters of 5-aminorepric acid and N-acyl-5-aminorepric acid. it can.
- 5-aminolevulinic acid ester for example, a linear, branched or cyclic alkyl ester having 1 to 24 carbon atoms which may have a substituent, preferably, for example, Methyl group, ethyl group, isopropyl group, n-hexyl group, cyclohexyl group, n-heptyl group, n-year-octyl group, n-nonyl group, n-dodecyl group, n-hexadecyl group, benzyl And 5-aminolevulinic acid ester having an ester residue such as a phenethyl group, a 3-phenyl pill group, a hydroxyethy
- examples of the substituent that these alkyl groups may have include a hydroxy group, an alkoxy group, a phenyl group, a benzyl group, and a hydroxymethyl group.
- N-acyl mono-aminolevulinic acid the amino group of 5-: ⁇ -minolevulinic acid is acylated with, for example, an alkanol group having 1 to 24 carbon atoms, an aromatic acyl group, a benzyloxycarbonyl group, etc. Compound.
- preferred N-acyl groups include, for example, acetyl group, n-pentanoyl group, n-hexanol group, n-nonanol group, benzoyl group, benzyloxycarbonyl group and the like. Can do.
- esters of 5-aminorepric acid and N-acyl-5-aminolevulinic acid can be produced, for example, by a known chemical synthesis method such as the method described in Japanese Patent Application Laid-Open No. HEI 93/360. it can. In addition to the chemical synthesis, it can be produced by any method of production using microorganisms or production using enzymes. In addition, a crude product containing the target product obtained in the production process can be used without separation and purification as long as these crude product does not contain harmful substances. 5-Aminorepric acid and its salts and derivatives can be used alone or as a mixture of two or more thereof.
- the iron compound of the present invention is not particularly limited as long as it is a compound having iron in the molecule.
- ferrous citrate, sodium iron citrate, iron iron citrate, iron acetate, iron oxalate, and succinic acid for example, ferrous citrate, sodium iron citrate, iron iron citrate, iron acetate, iron oxalate, and succinic acid.
- Ferrous iron, succinic acid Sodium iron phenate, ferrous pyrophosphate, ferric pyrophosphate, heme iron, dextran iron, iron lactate, ferrous dalconate, sodium diethylenetriaminepentaacetate, ammonium diethylenetriaminepentaacetate, ammonium diamine triacetate
- the hair restorer of the present invention preferably contains urea as an active ingredient.
- Urea is a colorless to white crystal or crystalline powder, is soluble in water, is slightly soluble in ethanol, and can be made into various dosage forms such as lotions and creams as external preparations. In addition, it has high affinity with the skin and has physical properties suitable as a component of a hair restorer.
- Urea varies depending on the base material and other components used in combination, but for the hair restorer of the present invention, 0.1 to 40 ( ⁇ / ⁇ %: weight ratio), preferably 0.1 to L It can be blended at a rate of 0%.
- urea to be used commercially available urea can be used as it is.
- excipients commonly used for hair growth agents vasodilators (salt carpronium, nicotinic acid benzyl, senpri extract, fonanine ginseng extract, vitamin ⁇ acetate, red pepper tincture, etc.), anti-histamine agent (Diphenhydramine hydrochloride, isothipentyl hydrochloride, etc.), anti-inflammatory agents (darlicyl retinoic acid, guaizlene, etc.), bactericides (chlorhexidine darconate, isopropylmethylphenol, quaternary ammonium salt, Hinokitiol, piroctone olamine, etc.), moisturizers (sodium hyaluronate, chondroitin sulfate, etc.), various animals and plants (yichi, potampi, raspberry, hypericum, adduct, bean sprout, raspberry, comfrey, ashipura, saffron , San
- the hair-restoring agent of the present invention is characterized by containing 5-aminorepric acid or a salt thereof, or a derivative thereof and an iron compound, and the dosage form includes powders, liquids, and ointments. Either is acceptable. It can be prepared into dosage forms such as lotions, emulsions, creams (ointments), gels, aerosols, etc. in accordance with commonly used methods (for example, the methods prescribed in the Japanese Pharmacopoeia No. 12). In addition, 5-aminolevulinic acid or a salt thereof, or a derivative thereof and an iron compound can be applied to the same affected area as separate dosage forms.
- the above-described hair growth agent of the present invention is preferably administered transdermally to the affected area by spraying, applying, poultice, or the like, but can also be appropriately transdermally applied to the entire scalp.
- the active ingredient 5-aminolevulinic acid or its salts and derivatives is l O g in terms of 5-aminolevric acid hydrochloride: L 0 mg, preferably 100 zg -5 mg More preferably, it is preferably administered at a rate of 1 mg to 5 mg.
- the dose of the iron compound combined with 5-aminorepric acid, etc. is 50 to 50 mg per iron equivalent, preferably 500 to 25 mg, more preferably 5 to 25 mg under the same conditions.
- a method of transdermally administering the hair restorer of the present invention by a method such as application from the evening to the night and washing it away in the eyelid is suitable.
- it is not limited to such a dosage form.
- One of the features of the hair restorer and hair growth method of the present invention is that it does not require the strict light-shielding treatment that was necessary in the case of single administration (application, etc.) of 5-aminolevulinic acid. It is desirable to avoid excessive light irradiation.
- the administration method of the present invention is carried out with 3 months as 1 course, and in many cases, the hair growth effect such as reduction of hair loss and appearance of new hair is exhibited from the third day. It can be used continuously, but once the effect is stable, once the administration is stopped, the effect can be expected again by resuming the administration after 3 months.
- a hair restorer similar to Example 1 was prepared except that 3 g of 5-aminolevulinic acid hydrochloride of Example 1 was used.
- Example 1 A hair restorer similar to that of Example 1 was prepared except that 1 g of ferrous citrate of Example 1 was used. As a result, almost the same effect as Example 1 was obtained.
- a hair restorer similar to that of Example 1 was prepared except that the ferrous citrate lg of Example 1 was changed to 4 g of diethylenetriaminepentaacetic acid ammonium ammonium. was gotten.
- Example 1 A hair restorer similar to Example 1 was prepared except that urea of Example 1 was not blended. As a result, almost the same effect as Example 1 was obtained except that the hair growth effect was slightly reduced.
- Photographs were taken at the start of application and 4 weeks later. The photograph is shown in Figure 2 (photo). As shown in Fig. 2, compared with the start of application, apparent hair growth was observed 4 weeks later, and visually apparent hair growth was observed.
- Example 7 'A gel-type hair restorer was prepared in the same manner as in Example 6 except that 5-aminolevulinic acid hydrochloride of Example 6 was changed to 5-aminolevulinic acid methyl ester. The effect was obtained.
- a gel-type hair restorer was prepared in the same manner as in Example 6 except that diethylenetriaminepentaacetic acid ammonium ammonium in Example 6 was changed to sodium diethylenetriaminepentaacetate, and an effect equivalent to or higher than that in Example 6 was obtained. was gotten.
- This hair growth agent was not subjected to strict light-shielding conditions when using conventional 5-aminolevulinic acid alone, and no hair removal was observed when a partial dose was exceeded.
- a decrease in the amount of hair loss attached to the pillowcase was observed.
- Photographs were taken at the start of application and 4 weeks later. The photograph is shown in Fig. 3 (photo). As shown in Fig. 3, apparent hair growth was observed after 4 weeks as compared to the start of application, and visually apparent hair growth was observed.
- a gel type hair restorer was prepared in the same manner as in Example 6 except that 5-aminolevulinic acid hydrochloride of Example 6 was changed to 5_aminolevulinic acid phenethyl ester, and the same effect as in Example 6 was obtained. Obtained.
- a cream type hair restorer was prepared in the same manner as in Example 10 except that 5 parts by weight of iron lactate in Example 10 was changed to 1 part by weight of ferrous dalconate. A similar effect was obtained.
- An aerosol hair restorer was prepared in the same manner as in Example 13 except that 1 part by weight of 5-aminolevulinic acid in Example 1 3 was changed to 1 part by weight of 5-aminolevulinic acid methyl ester. The same effect as 3 was obtained.
- Purified water is added to 70 parts by weight of ethyl alcohol, 5 parts by weight of propylene glycol, 0.5 parts by weight of 5-aminolevulinic acid, 2 parts by weight of triethylenetetraamine iron, and 100 parts by weight. Then, a lotion type hair restorer was prepared.
- This hair growth agent was not subjected to strict light-shielding conditions when using conventional 5-aminolevulinic acid alone, and no hair removal was observed when a partial dose was exceeded. In addition, the hair-growth effect was equivalent to or better than that of using 5-aminolevulinic acid alone.
- Purified water is added and stirred and dissolved so that ethyl alcohol is 45 parts by weight, 5-aminolevulinic acid is 1 part by weight, iron acetate is 2 parts by weight, 1,3-butanediol is 5 parts by weight, and the total amount is 100 parts by weight.
- ethyl alcohol 45 parts by weight
- 5-aminolevulinic acid is 1 part by weight
- iron acetate is 2 parts by weight
- 1,3-butanediol is 5 parts by weight
- the total amount is 100 parts by weight.
- 0.7 parts by weight of carboxybiyl polymer was dispersed, and then 0.7 parts by weight of diisopropanolamine.
- a gel-type hair restorer was prepared in the same manner as in Example 16 except that iron oxalate was used instead of iron acetate in Example 16. As a result, the same effect as in Example 16 was obtained. It was.
- Table 1 shows the 5-aminolevulinic acid (sometimes abbreviated as ALA) and iron compound of the present invention, and the compounding composition of these and urea in weight%.
- ALA 5-aminolevulinic acid
- ferrous citrate 0.4 g
- iron lactate 2.
- dulcon Ferrous acid 0.36 g was blended.
- 5-aminolevric acids and iron compounds especially sodium diethylenetriaminepentaacetate or ammonium ammonium diethylenetriaminepentaacetate, compared with the use of 5-aminolevulinic acid alone, hair removal, eyelashes, branches It is possible to provide a hair restorer that is free from problems such as hair and whitening, and that is not only an absolute requirement for light shielding but also simple to use, and that exhibits an equivalent or higher remarkable hair-growth effect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04747362.4A EP1743621B1 (en) | 2004-04-28 | 2004-07-06 | Hair restorer |
MXPA06012636A MXPA06012636A (es) | 2004-04-28 | 2004-07-06 | Regenerador de cabello. |
AU2004318989A AU2004318989B2 (en) | 2004-04-28 | 2004-07-06 | Hair restorer |
NZ550853A NZ550853A (en) | 2004-04-28 | 2004-07-06 | Hair restorer |
CN2004800428860A CN1942163B (zh) | 2004-04-28 | 2004-07-06 | 生发剂 |
ES04747362.4T ES2464169T3 (es) | 2004-04-28 | 2004-07-06 | Restaurador capilar |
BRPI0418784-9A BRPI0418784B1 (pt) | 2004-04-28 | 2004-07-06 | Composição restauradora de cabelo, e, método não-terapêutico para restaurar cabelo |
JP2005510828A JP3810018B2 (ja) | 2004-04-28 | 2004-07-06 | 育毛剤 |
US11/568,322 US8133479B2 (en) | 2004-04-28 | 2004-07-06 | Hair restorer |
PL04747362T PL1743621T4 (pl) | 2004-04-28 | 2004-07-06 | Środek do przywracania włosów |
CA2564043A CA2564043C (en) | 2004-04-28 | 2004-07-06 | Hair restorer |
US13/360,096 US8632759B2 (en) | 2004-04-28 | 2012-01-27 | Hair restorer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-134709 | 2004-04-28 | ||
JP2004134709 | 2004-04-28 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/568,322 A-371-Of-International US8133479B2 (en) | 2004-04-28 | 2004-07-06 | Hair restorer |
US13/360,096 Continuation US8632759B2 (en) | 2004-04-28 | 2012-01-27 | Hair restorer |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005105022A1 true WO2005105022A1 (ja) | 2005-11-10 |
Family
ID=35241403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/009894 WO2005105022A1 (ja) | 2004-04-28 | 2004-07-06 | 育毛剤 |
Country Status (13)
Country | Link |
---|---|
US (2) | US8133479B2 (ja) |
EP (1) | EP1743621B1 (ja) |
JP (1) | JP3810018B2 (ja) |
KR (1) | KR100873664B1 (ja) |
CN (1) | CN1942163B (ja) |
AU (1) | AU2004318989B2 (ja) |
BR (1) | BRPI0418784B1 (ja) |
CA (1) | CA2564043C (ja) |
ES (1) | ES2464169T3 (ja) |
MX (1) | MXPA06012636A (ja) |
NZ (1) | NZ550853A (ja) |
PL (1) | PL1743621T4 (ja) |
WO (1) | WO2005105022A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008126693A1 (ja) | 2007-04-05 | 2008-10-23 | Sbi Alapromo Co., Ltd. | ミトコンドリア障害脳疾患治療剤及び診断剤 |
JP2009298739A (ja) * | 2008-06-16 | 2009-12-24 | Sbi Alapromo Co Ltd | 光障害の軽減剤 |
JP2010095479A (ja) * | 2008-10-17 | 2010-04-30 | Milbon Co Ltd | 育毛剤組成物 |
JP2013032320A (ja) * | 2011-08-03 | 2013-02-14 | Milbon Co Ltd | 頭部用外用剤 |
JP2013032321A (ja) * | 2011-08-03 | 2013-02-14 | Milbon Co Ltd | 育毛剤組成物 |
JP2015028007A (ja) * | 2013-07-05 | 2015-02-12 | 富士フイルム株式会社 | ジヒドロテストステロン誘導型インターロイキン産生抑制剤 |
CN104940903A (zh) * | 2015-07-13 | 2015-09-30 | 董耀蔚 | 一种促进毛发快速生长的组合物配方及其制备方法 |
WO2022158591A1 (ja) | 2021-01-25 | 2022-07-28 | 学校法人順天堂 | 肥大型心筋症治療剤 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005105022A1 (ja) * | 2004-04-28 | 2005-11-10 | Yoshiyasu Ito | 育毛剤 |
EP1878421B1 (en) * | 2005-04-28 | 2019-04-03 | SBI Pharmaceuticals Co., Ltd. | External preparation for skin |
FR2911495B1 (fr) * | 2007-01-23 | 2014-06-27 | Oreal | Utilisation cosmetique d'associations de fer pour le soin de la peau. |
ES2822122T3 (es) | 2008-04-22 | 2021-04-29 | Sbi Pharmaceuticals Co Ltd | Método de detección del cáncer de vejiga |
JP5496881B2 (ja) * | 2008-05-14 | 2014-05-21 | Sbiファーマ株式会社 | 男性不妊治療剤 |
TWI426133B (zh) * | 2008-05-30 | 2014-02-11 | Jfe Steel Corp | Production method of pig iron |
JP5665544B2 (ja) | 2008-10-27 | 2015-02-04 | Sbiファーマ株式会社 | 5−アミノレブリン酸若しくはその誘導体、又はそれらの塩を有効成分とする成人病の予防・改善剤 |
KR101034567B1 (ko) * | 2009-11-13 | 2011-05-12 | 이소영 | 탈모 방지 및 발모 촉진용 약물 전달 시스템 |
KR20120137506A (ko) | 2010-05-19 | 2012-12-21 | 고쿠리츠다이가쿠호징 도쿄다이가쿠 | 5-아미노레불린산 또는 그 유도체를 유효성분으로 하는 항말라리아약 |
WO2012092628A2 (en) * | 2010-12-31 | 2012-07-05 | Incube Labs, Llc | Patches and methods for the transdermal delivery of agents to treat hair loss |
KR101385196B1 (ko) | 2012-05-17 | 2014-04-14 | 주식회사 유니크메디케어 | 광 조사를 이용한 광감각제―펩타이드를 유효성분으로 포함하는 발모 개선 또는 촉진용 조성물 및 이를 이용한 방법 |
US20180311130A1 (en) * | 2015-07-31 | 2018-11-01 | Isdin, S.A. | Anti-hair loss lotion |
US20170172869A1 (en) * | 2015-12-17 | 2017-06-22 | Sidiram S. Ragoonath | Hair Growth Product |
CN108325086B (zh) * | 2017-01-18 | 2021-09-24 | 上海市皮肤病医院 | 一种光动力促进生发的方法,制剂和组件 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02108612A (ja) * | 1988-10-19 | 1990-04-20 | Shizen:Kk | 二価三価複合鉄塩配合化粧品 |
JPH049360A (ja) | 1990-04-11 | 1992-01-14 | Cosmo Sogo Kenkyusho:Kk | 5―アミノレブリン酸アルキルエステル又はその塩及びその製造方法並びにこれを有効成分とする除草剤 |
JPH08337515A (ja) * | 1995-04-11 | 1996-12-24 | Kashima Sekiyu Kk | 化粧料 |
JPH11116446A (ja) * | 1997-10-15 | 1999-04-27 | Shiseido Co Ltd | 頭部用外用剤 |
JPH11171852A (ja) * | 1997-12-12 | 1999-06-29 | Cosmo Sogo Kenkyusho Kk | 5−アルコキシアミドレブリン酸類又はその塩 |
JP2003095878A (ja) * | 2001-09-21 | 2003-04-03 | Lion Corp | 外用剤 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2106386A (en) * | 1981-05-27 | 1983-04-13 | Ralph Brooke | A composition for the treatment of scalp and hair to retard loss and maintain and enhance the growth of hair |
US5470876A (en) * | 1985-07-18 | 1995-11-28 | Proctor; Peter H. | Topical sod for treating hair loss |
ES2157424T3 (es) | 1995-03-10 | 2001-08-16 | Photocure Asa | Esteres de acido 5-aminolevulinico como agentes fotosensibilizantes en fotoquimioterapia. |
JPH08337563A (ja) * | 1995-04-11 | 1996-12-24 | Kashima Sekiyu Kk | N−アシルアミノ酸及びその塩 |
GB2314019B (en) * | 1996-06-10 | 2000-03-15 | Bio Scient Ltd | The use of L-Lysine in the treatment of hair loss |
US5945441A (en) * | 1997-06-04 | 1999-08-31 | Gpi Nil Holdings, Inc. | Pyrrolidine carboxylate hair revitalizing agents |
AU3104301A (en) * | 2000-01-20 | 2001-07-31 | Noven Pharmaceuticals, Inc. | Compositions and methods to effect the release profile in the transdermal administration of active agents |
US6376557B1 (en) * | 2000-03-16 | 2002-04-23 | Chanda Bhuwalka Zaveri | Methods for treating alopecia |
US20020146439A1 (en) * | 2000-03-31 | 2002-10-10 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins |
NO20002428D0 (no) * | 2000-05-10 | 2000-05-10 | Radiumhospitalets Forskningsst | Hudpreparat |
US6435193B1 (en) * | 2000-11-22 | 2002-08-20 | L'oreal S.A. | Hair relaxer compositions utilizing cation exchange compositions |
JP4754731B2 (ja) * | 2001-07-31 | 2011-08-24 | コスモ石油株式会社 | 豚成育促進剤及び豚成育促進方法 |
US20030212127A1 (en) | 2002-05-09 | 2003-11-13 | Bradley Pharmaceuticals, Inc. | Method of treating actinic keratosis |
AU2003221663A1 (en) * | 2003-04-23 | 2004-11-19 | Qlt Inc. | Hair growth |
WO2005105022A1 (ja) * | 2004-04-28 | 2005-11-10 | Yoshiyasu Ito | 育毛剤 |
-
2004
- 2004-07-06 WO PCT/JP2004/009894 patent/WO2005105022A1/ja active IP Right Grant
- 2004-07-06 NZ NZ550853A patent/NZ550853A/en not_active IP Right Cessation
- 2004-07-06 US US11/568,322 patent/US8133479B2/en not_active Expired - Fee Related
- 2004-07-06 JP JP2005510828A patent/JP3810018B2/ja not_active Expired - Lifetime
- 2004-07-06 BR BRPI0418784-9A patent/BRPI0418784B1/pt not_active IP Right Cessation
- 2004-07-06 AU AU2004318989A patent/AU2004318989B2/en not_active Ceased
- 2004-07-06 ES ES04747362.4T patent/ES2464169T3/es not_active Expired - Lifetime
- 2004-07-06 KR KR1020067023201A patent/KR100873664B1/ko active IP Right Grant
- 2004-07-06 PL PL04747362T patent/PL1743621T4/pl unknown
- 2004-07-06 MX MXPA06012636A patent/MXPA06012636A/es active IP Right Grant
- 2004-07-06 EP EP04747362.4A patent/EP1743621B1/en not_active Expired - Lifetime
- 2004-07-06 CA CA2564043A patent/CA2564043C/en not_active Expired - Fee Related
- 2004-07-06 CN CN2004800428860A patent/CN1942163B/zh not_active Expired - Fee Related
-
2012
- 2012-01-27 US US13/360,096 patent/US8632759B2/en not_active Expired - Lifetime
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02108612A (ja) * | 1988-10-19 | 1990-04-20 | Shizen:Kk | 二価三価複合鉄塩配合化粧品 |
JPH049360A (ja) | 1990-04-11 | 1992-01-14 | Cosmo Sogo Kenkyusho:Kk | 5―アミノレブリン酸アルキルエステル又はその塩及びその製造方法並びにこれを有効成分とする除草剤 |
JPH08337515A (ja) * | 1995-04-11 | 1996-12-24 | Kashima Sekiyu Kk | 化粧料 |
JPH11116446A (ja) * | 1997-10-15 | 1999-04-27 | Shiseido Co Ltd | 頭部用外用剤 |
JPH11171852A (ja) * | 1997-12-12 | 1999-06-29 | Cosmo Sogo Kenkyusho Kk | 5−アルコキシアミドレブリン酸類又はその塩 |
JP2003095878A (ja) * | 2001-09-21 | 2003-04-03 | Lion Corp | 外用剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1743621A4 |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008126693A1 (ja) | 2007-04-05 | 2008-10-23 | Sbi Alapromo Co., Ltd. | ミトコンドリア障害脳疾患治療剤及び診断剤 |
US8927532B2 (en) | 2007-04-05 | 2015-01-06 | Sbi Pharmaceuticals Co., Ltd. | Therapeutic agent and diagnostic agent for mitochondrial dysfunction brain diseases |
EP3281642A1 (en) | 2007-04-05 | 2018-02-14 | SBI Pharmaceuticals Co., Ltd. | Diagnostic agent for mitochondrial dysfunction brain diseases |
JP2009298739A (ja) * | 2008-06-16 | 2009-12-24 | Sbi Alapromo Co Ltd | 光障害の軽減剤 |
JP2010095479A (ja) * | 2008-10-17 | 2010-04-30 | Milbon Co Ltd | 育毛剤組成物 |
JP2013032320A (ja) * | 2011-08-03 | 2013-02-14 | Milbon Co Ltd | 頭部用外用剤 |
JP2013032321A (ja) * | 2011-08-03 | 2013-02-14 | Milbon Co Ltd | 育毛剤組成物 |
JP2015028007A (ja) * | 2013-07-05 | 2015-02-12 | 富士フイルム株式会社 | ジヒドロテストステロン誘導型インターロイキン産生抑制剤 |
CN104940903A (zh) * | 2015-07-13 | 2015-09-30 | 董耀蔚 | 一种促进毛发快速生长的组合物配方及其制备方法 |
CN104940903B (zh) * | 2015-07-13 | 2017-12-22 | 董耀蔚 | 一种促进毛发快速生长的组合物配方及其制备方法 |
WO2022158591A1 (ja) | 2021-01-25 | 2022-07-28 | 学校法人順天堂 | 肥大型心筋症治療剤 |
Also Published As
Publication number | Publication date |
---|---|
KR100873664B1 (ko) | 2008-12-11 |
PL1743621T3 (pl) | 2014-08-29 |
NZ550853A (en) | 2009-04-30 |
ES2464169T3 (es) | 2014-05-30 |
MXPA06012636A (es) | 2007-03-21 |
AU2004318989A1 (en) | 2005-11-10 |
BRPI0418784B1 (pt) | 2014-08-19 |
CA2564043C (en) | 2012-01-31 |
CN1942163A (zh) | 2007-04-04 |
CA2564043A1 (en) | 2005-11-10 |
JPWO2005105022A1 (ja) | 2007-09-13 |
PL1743621T4 (pl) | 2014-11-28 |
JP3810018B2 (ja) | 2006-08-16 |
EP1743621B1 (en) | 2014-03-05 |
EP1743621A1 (en) | 2007-01-17 |
US8133479B2 (en) | 2012-03-13 |
US20070249721A1 (en) | 2007-10-25 |
AU2004318989B2 (en) | 2007-08-09 |
KR20070087488A (ko) | 2007-08-28 |
EP1743621A4 (en) | 2009-05-06 |
BRPI0418784A2 (pt) | 2010-11-23 |
CN1942163B (zh) | 2010-11-24 |
US20120122974A1 (en) | 2012-05-17 |
US8632759B2 (en) | 2014-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3810018B2 (ja) | 育毛剤 | |
JP3991063B2 (ja) | 皮膚外用剤 | |
JPH08502509A (ja) | 化粧品組成物 | |
JPH07316023A (ja) | 育毛料 | |
JP2003073268A (ja) | 細胞賦活剤及びそれを含有する皮膚外用剤 | |
JPH11116423A (ja) | リン酸誘導体とメタ二亜硫酸塩に基づくアスコルビン酸安定化のためのシステムとそれを含有する組成物 | |
JP3644809B2 (ja) | 頭部用外用剤 | |
JP5374058B2 (ja) | グルタミン酸誘導体、不全角化抑制剤、毛穴縮小剤、肌荒れ防止・改善剤及び皮膚外用組成物 | |
JP2006028026A (ja) | 育毛剤 | |
JP4887050B2 (ja) | 不全角化抑制剤、毛穴縮小剤 | |
JP6852261B2 (ja) | アシル塩基性アミノ酸誘導体および生理活性物質を含むマルチラメラベシクル製剤 | |
JP2001288048A (ja) | 頭皮頭髪用組成物 | |
JP2011046690A (ja) | 育毛剤組成物 | |
JP5352100B2 (ja) | 皮膚外用組成物 | |
US10543227B2 (en) | Hair growth composition | |
JPH11255621A (ja) | 頭皮頭髪用化粧料 | |
JPH11263714A (ja) | 頭皮頭髪用化粧料 | |
JPH1025226A (ja) | 養毛・育毛料 | |
JP2004026812A (ja) | 養毛料 | |
JP3388928B2 (ja) | 養毛・育毛料 | |
JP2021123586A (ja) | 外用医薬組成物 | |
JPH11322546A (ja) | 頭皮頭髪用化粧料 | |
JPH09227328A (ja) | 化粧料 | |
JPH11152211A (ja) | 頭皮頭髪用化粧料 | |
JP2002363090A (ja) | 皮膚外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480042886.0 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005510828 Country of ref document: JP |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2564043 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004318989 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 550853 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/012636 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6437/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067023201 Country of ref document: KR Ref document number: 2004747362 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004318989 Country of ref document: AU Date of ref document: 20040706 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004318989 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004747362 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11568322 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 11568322 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2004318989 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: PI0418784 Country of ref document: BR Kind code of ref document: A2 Effective date: 20061026 |